| Document |
Document Title |
|
WO/2023/233164A1 |
Compounds of formula (I) wherein R1, R2 and R3 are as defined herein are able to rescue dysfunctional mitochondria and are therefore of use in the treatment and prevention of neurodegenerative disorders as well as acute radiation syndrom...
|
|
WO/2023/221961A1 |
The present invention relates to the technical field of pharmaceutics, and in particular to a triptolide lignocerate, a liposome thereof and a preparation method therefor. The chemical structural formula of the triptolide lignocerate is ...
|
|
WO/2023/179351A1 |
Provided is a preparation method for 7-oxotriptophenolide (compound 1). The method comprises the following steps: performing benzylic oxidation with a compound 4 to obtain a compound 5, then condensing with a hydroxylamine compound to ob...
|
|
WO/2023/143330A1 |
The present invention relates to the field of medicines. The present invention relates to a compound used as an anti-cancer and/or immune disease drug, and specifically relates to a tripterygium wilfordii diterpene epoxide. In particular...
|
|
WO/2023/138147A1 |
The present invention relates to the field of medicinal chemistry. Disclosed are a triptolide prodrug, a preparation method therefor and a pharmaceutical use thereof. The preparation steps are: 1, making triptolide react with acyl chlori...
|
|
WO/2023/082368A1 |
A 4-azasteroid compound, and a preparation method therefor and the use thereof. The structural formula thereof is as represented by the following formula I. The compound is obtained by means of an epoxy reaction of finasteride as a raw m...
|
|
WO/2023/070071A2 |
The technology disclosed herein provides (4aR,4bS,6aS,9aS,9bS)-1-(4-chlorobenzyl)-4a,6a-dimethyl-3,4,
4a,6,6a,8,9,9a,9b,10-decahydro-1H-indeno[5,4-f]quinoline-2,5
,7(4bH)-trione, identified as compound IB:10:D, and related compounds. Com...
|
|
WO/2022/261774A1 |
Novel chemical agents are described herein. More specifically, a novel inhibitor of 17β-HSD7 for decreasing estradiol concentrations while restoring dihydrotestosterone (DHT) concentrations in breast cancer cells is disclosed herein. In...
|
|
WO/2022/258035A1 |
Provided in the present invention are a choline carbonate prodrug, wherein the choline carbonate prodrug can be converted in vivo by plasma cholinesterase to release the choline carbonate prodrug of active compounds; a preparation method...
|
|
WO/2022/115381A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a p...
|
|
WO/2022/040487A1 |
This disclosure provides triptolide-conjugates, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, as well methods of using such compounds in the treatment of conditions/diseases, suc...
|
|
WO/2021/164155A1 |
The present invention relates to a cryptotanshinone derivative, a preparation method therefor and an application thereof in resisting neuroinflammation and neuroprotection. The cryptotanshinone derivative has the structure as shown in fo...
|
|
WO/2021/134272A1 |
Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in the preparation of anti-cancer dr...
|
|
WO/2020/096485A1 |
The invention relates to the field of medicine and to the chemical and pharmaceutical industry, and concerns agents for treating breast cancer. Proposed is the use of 3-O-sulfamoyloxy-7β-methyl-D-homo-6-oxa-8α-estra-1,3,5(10)
-triene-1...
|
|
WO/2020/096487A1 |
The invention relates to the field of medicine and to the chemical and pharmaceutical industry, and concerns agents for treating breast cancer. Described is the use of 3-O-sulfamoyloxy-7β-methyl-D-homo-6-oxaestra-1,3,5(10),8(9)
-tetraen...
|
|
WO/2020/056174A1 |
The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of fibrosis, nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
|
|
WO/2019/192031A1 |
Disclosed are a triptolide derivative and a preparation method therefor and the use thereof. The triptolide derivative has the structure as shown in general formula I, and the definition of each substituent is as described in the descrip...
|
|
WO/2019/140272A1 |
Provided herein is a compound of Formula (I-I), or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and met...
|
|
WO/2019/052477A1 |
Provided is the use of a class of tanshinone compounds for treating hemangioma; in particular, provided is the use of a class of compounds as shown in formula I below or a pharmaceutically acceptable salt thereof. The tanshinone compound...
|
|
WO/2019/029319A1 |
The present invention relates to a composition containing a limonin compound and a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof and a biguanide compound; the biguanide compound may be metformin or ...
|
|
WO/2018/222701A1 |
The present application relates to methods of treating or preventing a renal disease, disorder, or condition (e.g., age-, diabetes- and/or obesity-related renal disease, disorder, or condition) in a subject in need thereof, comprising ad...
|
|
WO/2018/206078A1 |
The present invention concerns cocrystals of finasteride and a carboxylic acid, a method of their preparation and a pharmaceutical formulation comprising said cocrystals. In addition the invention relates to said cocrystals for use in th...
|
|
WO/2018/201516A1 |
A compound and an application thereof for treatment of cataract. The structural formula of the compound is as shown in formula I. The compound of formula I, a prodrug thereof, or a pharmaceutically acceptable salt thereof, can be used to...
|
|
WO/2018/147345A1 |
Provided is a method by which a compound, which is useful as an intermediate and in which an oxo group is introduced specifically at the 15-position of a steroid skeleton, can be produced at a high yield without involving a complex proce...
|
|
WO/2018/134278A1 |
The present invention refers to a new process for the synthesis of (9β,10α)-pregn-4-ene-3,20-dione, commonly known as retroprogesterone, having the formula (1) shown below.
|
|
WO/2018/025083A1 |
The described invention relates to small molecule therapeutic compounds capable of reducing the incidence of intracerebral hemorrhage and brain microhemorrhages identified using zebrafish and mouse models of intracerebral hemorrhage and ...
|
|
WO/2018/019301A1 |
Provided is a compound represented by formula I, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, polycrystalline material, or precursor thereof, and a manufacturing method and pharmaceutical applicatio...
|
|
WO/2017/205964A1 |
Estrane-based and androstane-based aminosteroid derivatives are described herein. More specifically, the following piperazinyl-steroid compounds of Formula I, Formula II, Formula III, and Formula IV are described. The compounds display c...
|
|
WO/2017/195804A1 |
Provided is a crystalline polymorph A of 15β-hydroxy-osaterone acetate having improved stabilities (storage stability, pulverization stability, and absorption property). Diffraction peaks characteristic of this crystalline polymorph A o...
|
|
WO/2017/186135A1 |
Disclosed in the present invention are a compound and an application thereof for the treatment of cataracts. The structural formula of the compound is shown in formula I. The compound shown in formula I, a prodrug thereof, or a pharmaceu...
|
|
WO/2017/190034A1 |
The present invention provides a compound having the structure: formula (I), for use in combinatoin with an anti-tuberculosis drug for treating a subject infected with M. tuberculosis.
|
|
WO/2017/159922A1 |
The present invention relates to a composition for preventing hair loss and, more specifically, to a compound having a structure in which finasteride and a peptide are linked through a covalent bond and a pharmaceutical composition or a ...
|
|
WO/2017/001439A1 |
Novel homo-aza-steroidal esters with alkylating bis(2-chloroethyl)aminophenoxy propanoic acid and substituted derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of can...
|
|
WO/2016/181312A1 |
The present technology provides polycyclic epoxides of Formula I, compositions comprising such expoxides and methods of using such epoxides. In particular, these compounds are useful for inhibiting cancer cell proliferation and tumor ang...
|
|
WO/2016/084790A1 |
The present invention provides a compound represented by general formula (I) which has excellent retinoic acid receptor-related orphan receptor γt inhibitory activity and IL-17 production inhibitory activity, or a pharmaceutically accep...
|
|
WO/2015/188611A1 |
A limonin extraction method, comprising the following steps: step one, raw material digesting or juicing: directly soaking raw material in water or using a presser to directly juice the raw material to obtain the extract; step two, addin...
|
|
WO/2015/085447A1 |
Disclosed in the present invention are triptolide-nucleic acid aptamer derivatives, and a preparation method and use thereof. The structure of the triptolide-nucleic acid aptamer derivatives is as shown by formula I, wherein the definiti...
|
|
WO/2015/070713A1 |
The present invention relates to the field of medicinal chemistry, and in particular relates to limonin oxime ether derivatives (I) and (II), and the preparation method and the medicinal thereof. The pharmacological experiments show that...
|
|
WO/2015/013453A1 |
The invention provides methods and compositions for use of desmopressin in combination with a 5-alpha reductase inhibitor. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.
|
|
WO/2014/059314A1 |
This document relates to compounds and compositions useful for treating cancers, such as brain and nervous system cancers.
|
|
WO/2014/056401A1 |
Disclosed are a double-bond substituted tripterygium wilfordii lactone derivative as represented by formula (I), or pharmaceutically acceptable salt or hydrate thereof, or optical isomer thereof, wherein R1=OH, R2=H, or R1=H, R2=OH. Also...
|
|
WO/2013/106975A1 |
The present invention provides extraction of brassinolide analogs from plants and applications thereof, comprising applications in promoting plant growth, resisting low temperature, and resisting and high salt. In addition, the present i...
|
|
WO/2012/116664A1 |
The invention relates to a method for stimulating the natural defence and the induction of resistance to diseases in plants, by means of the simultaneous activation of genes related to the pathway of salicylic acid, to the pathway of jas...
|
|
WO/2012/083112A2 |
Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula (Z), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), or (XVII). Also described herein are pharmaceutical compositions that include at least one compound...
|
|
WO/2012/035553A1 |
Provided is a process for preparing androstenone derivatives, specifically 3-oxo-4-aza-5α-androstene-17β-carboxylic acid of Formula I, a key intermediate for dutasteride.
|
|
WO/2011/054929A2 |
The invention relates to a method for producing triptolide from a suspension cell culture of Tripterygium sp., to a triptolide-enriched extract obtainable by means of extraction from the culture medium of an in vitro culture of dediffere...
|
|
WO/2011/054182A1 |
Sodium transhinone IIA sulfonate hydrate and preparation method and use thereof are disclosed. The molecular formula of said sodium transhinone IIA sulfonate hydrate is C19H17NaO6 . nH2O, wherein n is 0.5-4.0. The storage stability of th...
|
|
WO/2011/010682A1 |
Disclosed is a sterol derivative, which has an effect of promoting the proliferation of nerve stem cells, or a pharmaceutically acceptable salt of the same. Specifically disclosed is a sterol derivative represented by general formula (I)...
|
|
WO/2010/112079A1 |
The present invention relates to a process of separation of 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid, which brings to 4-aza-androst-1-ene-17-oic containing less than 0.05% w/w of 4-aza-androstan-17-oic acid, with ...
|
|
WO/2009/136629A1 |
Disclosed is a method for the screening of a compound having an activity to selectively modulate an androgen receptor. The method comprises the steps of: contacting a substance to be tested with a prostate cancer cell and measuring the ...
|
